Table 1. Study Population.
Characteristic | No. (%) |
---|---|
Patients, No. | 340 |
EuroSCAR score, median (IQR) [range] | 8 (7-9) [5-12] |
Probable AGEP (score 5-7) | 128 |
Definite AGEP (score 8-12) | 212 |
Age, mean (SD) [range], y | 57.8 (17.4) [18-90] |
Sex | |
Male | 126 (37.1) |
Female | 214 (62.9) |
Ethnicity | |
Hispanic or Latino | 20 (5.9) |
Not Hispanic or Latino | 239 (70.3) |
Not specified | 81 (23.8) |
Racea | |
American Indian/Alaska Native | 1 (0.3) |
Asian | 15 (4.4) |
Black or African American | 58 (17.1) |
Native Hawaiian or Pacific Islander | 1 (0.3) |
White | 206 (60.6) |
Other | 20 (5.9) |
Not specified | 39 (11.5) |
Associated comorbidities | |
Diabetes | 97 (28.5) |
Chronic kidney disease | 79 (23.2) |
Psoriasisb | 24 (7.1) |
Plaque | 8 (33.3) |
Pustular | 7 (29.2) |
Erythrodermic | 4 (16.7) |
Inverse | 1 (4.2) |
Guttate | 0 |
Type unknown | 9 (37.5) |
Psoriatic arthritis | 3 (0.9) |
History of drug rash | |
Hypersensitivity (urticaria, anaphylaxis, or angioedema) | 64 (18.8) |
Morbilliform | 27 (7.9) |
Lichenoid | 2 (0.6) |
Fixed drug eruption | 3 (0.9) |
History of SCAR | |
DRESS | 6 (1.8) |
SJS/TEN | 10 (2.9) |
Abbreviations: AGEP, acute generalized exanthematous pustulosis; DRESS, drug reaction with eosinophilia and systemic symptoms; SCAR, severe cutaneous adverse reaction; SJS/TEN, Stevens-Johnson syndrome/toxic epidermal necrolysis.
Classifications were made based on how patient demographic data were available within the electronic medical records at home institution of Mass General Brigham. These were the choices available to participating study sites in the standardized data entry form. Collaborators then chose from these available choices based on what information was available in the demographic data of their home institution. Other race was chosen when a patient’s racial demographic information was not available or was listed as something other than one of the available choices in the standardized data entry form.
All subtypes of psoriasis reported for each patient were included.